28 May 2020 : Special report
A Novel Vaccine Employing Non-Replicating Rabies Virus Expressing Chimeric SARS-CoV-2 Spike Protein Domains: Functional Inhibition of Viral/Nicotinic Acetylcholine Receptor Complexes
Michelle L. Stefano1ABCDEF, Richard M. Kream23ABCDEF, George B. Stefano23ABCDEF*DOI: 10.12659/MSM.926016
Med Sci Monit 2020; 26:e926016
Abstract
The emergence of the novel β-coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a global pandemic of coronavirus disease 2019 (COVID-19). Clinical studies have documented that potentially severe neurological symptoms are associated with SARS-CoV-2 infection, thereby suggesting direct CNS penetration by the virus. Prior studies have demonstrated that the destructive neurological effects of rabies virus (RABV) infections are mediated by CNS transport of the virus tightly bound to the nicotinic acetylcholine receptor (nAChR). By comparison, it has been hypothesized that a similar mechanism exists to explain the multiple neurological effects of SARS-CoV-2 via binding to peripheral nAChRs followed by orthograde or retrograde transport into the CNS. Genetic engineering of the RABV has been employed to generate novel vaccines consisting of non-replicating RABV particles expressing chimeric capsid proteins containing human immunodeficiency virus 1 (HIV-1), Middle East respiratory syndrome (MERS-CoV), Ebolavirus, and hepatitis C virus (HCV) sequences. Accordingly, we present a critical discussion that integrates lessons learned from prior RABV research and vaccine development into a working model of a SARS-CoV-2 vaccine that selectively targets and neutralizes CNS penetration of a tightly bound viral nAChR complex.
Keywords: Coronavirus, COVID-19, Rabies virus, Receptors, Nicotinic, Vaccines, Betacoronavirus, COVID-19, COVID-19 Vaccines, Coronavirus Infections, Pandemics, Pneumonia, Viral, Protein Domains, SARS-CoV-2, Spike Glycoprotein, Coronavirus, Viral Vaccines, Virus Replication
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
09 Apr 2024 : Clinical Research
Correlation between Thalamocortical Tract and Default Mode Network with Consciousness Levels in Hypoxic-Isc...Med Sci Monit In Press; DOI: 10.12659/MSM.943802
19 Apr 2024 : Clinical Research
Comparative Analysis of Postoperative Sagittal Balance in Expansive Open-Door Laminoplasty versus Laminecto...Med Sci Monit In Press; DOI: 10.12659/MSM.943057
20 Mar 2024 : Clinical Research
Prevalence and Management of Chronic Pain, Including Neuropathic Pain, in Dialysis Patients with End-Stage ...Med Sci Monit In Press; DOI: 10.12659/MSM.943808
15 Mar 2024 : Clinical Research
Impact of Cluster Nursing Intervention on ICU Patients' Psychological Well-Being and Complications Associat...Med Sci Monit In Press; DOI: 10.12659/MSM.942855
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952